Tubulin inhibitor SP-1-39 with anti-PD-L1 for enhanced cancer immunotherapy

SP-1-39, a novel tubulin inhibitor, enhances PD-L1 expression on tumor cells, increasing susceptibility to anti-PD-L1 therapy. This combination aims to improve T cell-mediated cancer treatment efficacy by overcoming resi...